Equity Overview
Price & Market Data
Price: $31.05
Daily Change: -$1.02 / 3.29%
Range: $30.20 - $31.92
Market Cap: $1,835,213,312
Volume: 416,144
Performance Metrics
1 Week: 4.58%
1 Month: 3.09%
3 Months: -29.61%
6 Months: -41.19%
1 Year: -37.63%
YTD: -42.01%
Company Details
Employees: 81
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.